

POZEN[®]
INC.

Results of Phase 3 Pivotal Trials

THE JOURNEY CONTINUES >>

POZEN/GSK's Next Generation Migraine Product Treximet

- First triptan-based product with multiple mechanism of action
- Formulation utilizes GSK's RT Technology™
 - Improved sumatriptan disintegration and absorption vs standard tabs
 - Extended absorption of naproxen sodium
- Expected benefits of Trexima over triptan monotherapy
 - Faster onset of pain relief
 - Longer duration of action
 - Effective in more patients
 - Similar tolerance to triptan monotherapy
 - Superior benefit/risk profile

Treximet Phase 3 Endpoints

Efficacy as Migraine Drug

- Demonstrate superiority to placebo for relief of pain and associated symptoms (nausea, photophobia and phonophobia) at 2 hours

Satisfy Combination Drug Rule

- Show sustained pain free superiority against sumatriptan alone and naproxen alone
 - Sustained Pain Free Definition-No pain at 2 hours and no relapse nor use of rescue medicine through 24 hours


Phase 3 Trials: Clear Clinical Benefit

<i>Treximet</i>	301	302
vs Sumatriptan 24 Hour Sustained Pain Free	P<0.001	P=0.009
vs Naproxen 24 Hour Sustained Pain Free	P<0.001	P<0.001
vs Placebo – 2 Hour Photophobia Phonophobia Pain	P<0.001	P<0.001
Nausea – 2 Hour	NS*	P=0.007

* Reached statistical superiority at 3 hours and maintained through 24 hours

Migraine Efficacy at 2 Hours Co-primary Endpoints

POZEN[®]
INC.



Overall Summary (SumaRT/Nap)

- **Effective Migraine Medication (compared to PBO)**
 - 2 hour endpoints: in both studies, superior for pain, photo and phonophobia
 - Nausea: in 1 of 2 studies, superior
 - Nausea: when pooled & adjusted for baseline imbalance, superior at 2 hours and sustained for 24 hours
- **Superior to Sumatriptan**
 - 2 and 4 hour Pain Relief
 - 4 hour Relief in at least 2/3 Associated Symptoms
- **Tolerable Clinical Safety Profile**
 - AEs were similar to individual components
 - Incidence of AEs were not clinically significantly higher with SumaRT/Nap compared to sumatriptan alone

POZEN[®]
INC.

Results of Phase 3 Pivotal Trials

THE JOURNEY CONTINUES >>